Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / December 18, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Bicycle Therapeutics plc ("Bicycle" or "the Company") (NASDAQ:BCYC). Investors who purchased Bicycle securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/BCYC.

Bicycle Investigation Details

On October 31, 2025, RBC Capital Markets analyst Leonid Timashev downgraded Bicycle to Sector Perform from Outperform, citing delays in development of zelenectide pevedotin, which is in phase 2/3 development for metastatic urothelial cancer, due to pushing dose selection to the first quarter of 2026. Timashev noted that the urothelial cancer treatment space is becoming increasingly competitive and asserted that any further delays from Bicycle will only help sales of a competing Pfizer product. Following the downgrade, Bicycle’s American Depositary Receipt ("ADR") price fell $0.69 per ADR, or 7.88%, to close at $8.07 per ADR on October 31, 2025.

What’s Next for Bicycle Investors?

If you are aware of any facts relating to this investigation or purchased Bicycle securities, you can assist this investigation by visiting the firm’s site: bgandg.com/BCYC. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Bicycle Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Bicycle Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire

comtex tracking

COMTEX_471216150/2457/2025-12-18T12:50:32

Scroll to Top